Brainsway (BWAY) to Release Earnings on Wednesday

Key Points

• Brainsway (BWAY) is set to release its Q2 2025 earnings on August 5th, with analysts predicting earnings of $0.07 per share and revenue of $12.34 million.
• The company recently reported a net margin of 9.01% and a return on equity of 7.35% in its last earnings results, beating expectations with a reported EPS of $0.04.
• HC Wainwright has reiterated a "buy" rating for Brainsway with a price target of $16.00 per share, indicating positive sentiment from analysts.

Brainsway (NASDAQ:BWAY - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Brainsway to post earnings of $0.07 per share and revenue of $12.34 million for the quarter. Brainsway has set its FY 2025 guidance at EPS.

Brainsway (NASDAQ:BWAY - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. Brainsway had a net margin of 9.01% and a return on equity of 7.35%. The business had revenue of $11.54 million for the quarter, compared to analyst estimates of $11.45 million. On average, analysts expect Brainsway to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Brainsway Stock Down 1.8%

Shares of BWAY stock traded down $0.21 during trading hours on Friday, reaching $11.47. 18,876 shares of the stock traded hands, compared to its average volume of 46,583. Brainsway has a 1-year low of $5.98 and a 1-year high of $13.65. The business has a fifty day moving average price of $11.73 and a 200 day moving average price of $10.42. The firm has a market capitalization of $216.78 million, a PE ratio of 57.35 and a beta of 1.42.

Institutional Trading of Brainsway

An institutional investor recently raised its position in Brainsway stock. NewEdge Advisors LLC grew its holdings in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) by 61.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,828 shares of the company's stock after buying an additional 7,549 shares during the quarter. NewEdge Advisors LLC owned 0.11% of Brainsway worth $188,000 as of its most recent filing with the SEC. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Brainsway in a research report on Monday, June 9th.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.